← Oncology Approval Tracker

FDA DECISION ·

Armlupeg

pegfilgrastim-unne · Lupin

Biosimilar approvalBiosimilarFebrile neutropenia prevention
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Neulasta biosimilar for decreasing infection manifesting as febrile neutropenia in adults and children from birth with nonmyeloid malignancies receiving myelosuppressive anticancer therapy associated with a clinically significant risk of febrile neutropenia.

LAMPGEN ANALYSIS

Why it matters

This long-acting G-CSF biosimilar adds a supportive care option during myelosuppressive treatment.

What research teams should watch

Align administration with the chemotherapy calendar and check the prescribed device and weight-based dose when applicable.

PRIMARY RECORDS

Sources